ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Plasma Alzheimer's disease biomarker variability: Amyloid-independent and amyloid-dependent factors.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Kidney Function and Blood and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Related Dementias: Systematic Review and Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2026Pooled it
- The Impact of 5-Hydroxytryptophan Supplementation on Cognitive Function and Mood in Singapore Older Adults: A Randomized Controlled Trial.Nutrients · 2025Trial
- An Exploratory Six-Probe Blood RNA Signature for Predicting 12-Month Cognitive Decline Along the Alzheimer's Disease Continuum: An Interpretable Machine Learning Study.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Longitudinal plasma p-tau217 as a marker for tracking progression and predicting cognitive decline in Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer's disease neuroimaging initiative cohort.The journal of prevention of Alzheimer's disease · 2026Article
- Electronic Health Records to Test Multimorbidity Influences to Plasma Biomarker Interpretation for Alzheimer's Disease.Annals of neurology · 2026Article
- Anemia, iron deficiency, and blood biomarkers for Alzheimer disease: clinical interpretation and dementia risk stratification.Frontiers in nutrition · 2026Review
- Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain-Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease.Journal of neurochemistry · 2025Article
- Prognostic Value of A/T/N Biomarkers: Comparing Plasma and Imaging Modalities in Alzheimer Disease.Clinical nuclear medicine · 2025Article
- Plasma phosphorylated tau 217 and amyloid‑β 42/40 for amyloid risk in subgroups.Alzheimer's research & therapy · 2025Article
- P-tau217 as a Biomarker in Alzheimer's Disease: Applications in Latin American Populations.International journal of molecular sciences · 2025Review
- Standardized Procedures for Blood and Cerebrospinal Fluid Collection and Storage in Neurodegenerative Biomarker Research: A Comprehensive Review.Dementia and neurocognitive disorders · 2025Review
- Spotlight on Alzheimer's disease and related dementias research in East Asia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkers.JAMA network open · 2025Article
- The performance of plasma p-tau217 in Black middle-aged and older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Plasma Alzheimer's disease biomarker variability: Amyloid-independent and amyloid-dependent factors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionWe aimed to investigate which factors affect plasma biomarker levels via amyloid beta (Aβ)-independent or Aβ-dependent effects and improve the predictive performance of these biomarkers for Aβ positivity on positron emission tomography (PET).
methodsA total of 2935 participants underwent blood sampling for measurements of plasma Aβ42/40 ratio, phosphorylated tau 217 (p-tau217; ALZpath), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) levels using single-molecule array and Aβ PET. Laboratory findings were collected using a routine blood test battery.
resultsAβ-independent factors included hemoglobin and estimated glomerular filtration rate (eGFR) for p-tau217 and hemoglobin, eGFR, and triiodothyronine (T DISCUSSION: Our findings highlight the importance of accurately interpreting plasma biomarkers for predicting Aβ uptake in real-world settings. HIGHLIGHTS: We investigated factor-Alzheimer's disease plasma biomarker associations in a large Korean cohort. Hemoglobin and estimated glomerular filtration rate affect the biomarkers independently of brain amyloid beta (Aβ). Apolipoprotein E genotypes and body mass index status affect the biomarkers dependent on brain Aβ. Addition of Aβ-independent factors shows negligible effect in predicting Aβ positivity. Adjusting for Aβ-dependent factors shows a modest effect in predicting Aβ positivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.